Skip to main content
SpringerLink
Log in

CHMP confirms recommendations for Tysabri and SGLT2 inhibitors

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. SGLT2 = sodium-glucose transporter 2

  2. see Reactions 1590 p7; 1

  3. see Reactions 1590 p6; 2

References

  1. European Medicines Agency. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. Internet Document : 26 Feb 2016. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/02/news_detail_002476.jsp&mid=WC0b01ac058004d5c1

  2. European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. Internet Document : 26 Feb 2016. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/02/news_detail_002477.jsp&mid=WC0b01ac058004d5c1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CHMP confirms recommendations for Tysabri and SGLT2 inhibitors. Reactions Weekly 1592, 2 (2016). https://doi.org/10.1007/s40278-016-15430-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-15430-z

Search

Navigation